These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28320023)

  • 1. [Update Opipramol].
    Gahr M; Hiemke C; Connemann BJ
    Fortschr Neurol Psychiatr; 2017 Mar; 85(3):139-145. PubMed ID: 28320023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern indications for the use of opipramol.
    Krysta K; Murawiec S; Warchala A; Zawada K; Cubała WJ; Wiglusz MS; Jakuszkowiak-Wojten K; Krzystanek M; Krupka-Matuszczyk I
    Psychiatr Danub; 2015 Sep; 27 Suppl 1():S435-7. PubMed ID: 26417811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group.
    Möller HJ; Volz HP; Reimann IW; Stoll KD
    J Clin Psychopharmacol; 2001 Feb; 21(1):59-65. PubMed ID: 11199949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Opipramol (Insidon) in the treatment of somatoform disorders].
    Freyberger HJ; Grabe HJ; Maier W; Janca A; Stoll KD
    Fortschr Neurol Psychiatr; 1998 Dec; 66 Suppl 1():S25-30. PubMed ID: 9922924
    [No Abstract]   [Full Text] [Related]  

  • 5. Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial.
    Volz HP; Möller HJ; Reimann I; Stoll KD
    Eur Neuropsychopharmacol; 2000 May; 10(3):211-7. PubMed ID: 10793324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Opipramol in anxiety and somatoform disorders. Results of a controlled study].
    Volz HP; Möller HJ
    Fortschr Neurol Psychiatr; 1998 Dec; 66 Suppl 1():S21-4. PubMed ID: 9922923
    [No Abstract]   [Full Text] [Related]  

  • 7. Mania, a probable adverse drug reaction of opipramol in a patient with generalized anxiety disorder.
    Kar SK; Garg K
    Aust N Z J Psychiatry; 2015 Dec; 49(12):1225-6. PubMed ID: 25900970
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis caused by antidepressive therapy with maprotiline and opipramol.
    Braun JS; Geiger R; Wehner H; Schäffer S; Berger M
    Pharmacopsychiatry; 1998 Jul; 31(4):152-5. PubMed ID: 9754852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Opipramol in behavioral pharmacologic anxiety and depression models].
    Gentsch C
    Fortschr Neurol Psychiatr; 1998 Dec; 66 Suppl 1():S17-20. PubMed ID: 9922922
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand.
    Müller WE; Siebert B; Holoubek G; Gentsch C
    Pharmacopsychiatry; 2004 Nov; 37 Suppl 3():S189-97. PubMed ID: 15547785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials with sigma ligands.
    Volz HP; Stoll KD
    Pharmacopsychiatry; 2004 Nov; 37 Suppl 3():S214-20. PubMed ID: 15547788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dopamine Receptor Antagonism of Opipramol: Relevance to Parkinsonism?
    Rozanski V; Laux G; Schwarz J
    Clin Neuropharmacol; 2019; 42(3):77-79. PubMed ID: 30829882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific modulation of sigma binding sites by the anxiolytic drug opipramol.
    Holoubek G; Müller WE
    J Neural Transm (Vienna); 2003 Oct; 110(10):1169-79. PubMed ID: 14523629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opipramol improves subjective quality of sleep the night prior to surgery: confirmatory testing of a double-blind, randomized clinical trial.
    Hueppe M; Hartge D; Stoll KD; Ros A; Schmucker P; Gerlach K
    Neuropsychobiology; 2011; 64(1):24-31. PubMed ID: 21577010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of opipramol from a film-coated tablet, a sugar-coated tablet and an aqueous solution in healthy volunteers.
    Kees F; Jehkul A; Bucher M; Mair G; Kiermaier J; Grobecker H
    Arzneimittelforschung; 2003; 53(2):87-92. PubMed ID: 12642963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of opipramol as an evening anaesthesiologic premedication.
    Gerlach K; Uhlig T; Plathof J; Klassen A; Stoll KD; Schmucker P; Hueppe M
    Neuropsychobiology; 2002; 46(3):161-6. PubMed ID: 12422064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Actual therapeutic options in the treatment of generalized anxiety disorders].
    Delini-Stula A; Bondolfi G; Holsboer-Trachsler E
    Rev Med Suisse; 2010 Jun; 6(255):1370-4. PubMed ID: 20684132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: clinical and theoretical implications.
    Casacalenda N; Boulenger JP
    Can J Psychiatry; 1998 Sep; 43(7):722-30. PubMed ID: 9773222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression.
    Möller HJ; Volz HP; Stoll KD
    Acta Neuropsychiatr; 2003 Aug; 15(4):217-26. PubMed ID: 26983569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mania induced by opipramol.
    Firoz K; Khaleel A; Rajmohan V; Kumar M; Raghuram T
    Indian J Psychol Med; 2015; 37(1):96-8. PubMed ID: 25722522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.